With record fund flows, biotech a top sector for investors heading into 3Q20

Investors expect the massive inflows to biotech to continue over the next quarter as the sector is viewed as a top defensive pick in a struggling global economy that is unlikely to improve until the first COVID-19 vaccines roll out, or therapeutics gain approval that make a meaningful difference.

The broad interest in the sector means capital markets are likely to remain active even in the face of the upcoming U.S. presidential election...